$ALZN
Alzamend Neuro, Inc. Stock $alzn

$alzn Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000121465922008985 Filed on July 19, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.660M	$2.212M	$7.118M
YoY Change	19.41%	138.5%	95.49%
% of Gross Profit
Research & Development	$1.376M	$1.661M	$5.201M
YoY Change	50.15%	467.54%	296.83%
% of Gross Profit
Depreciation & Amortization	$7.097K	$3.550K	$3.549K
YoY Change
% of Gross Profit
Operating Expenses	$1.376M	$3.873M	$5.201M
YoY Change	-40.34%	217.45%	296.83%
Operating Profit	-$3.036M		-$12.32M
YoY Change	31.62%		148.78%
Interest Expense	$1.532K	-$600.00	$46.52K
YoY Change	-111.24%	-98.37%	-67.33%
% of Operating Profit
Other Income/Expense, Net	-$1.532K		-$42.52K
YoY Change	-88.76%		-55.09%
Pretax Income	-$3.037M	-$3.869M	-$12.36M
YoY Change	30.92%	207.87%	144.96%
Income Tax
% Of Pretax Income
Net Earnings	-$3.037M	-$3.869M	-$12.36M
YoY Change	30.92%	207.87%	144.96%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03		-$0.14
Diluted Earnings Per Share	-$31.16K	-$44.01K	-$138.8K
COMMON SHARES
Basic Shares Outstanding	95.48M shares		89.10M shares
Diluted Shares Outstanding	97.48M shares		89.10M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.53M	$14.06M	$14.06M
YoY Change	-26.19%	628.97%	628.97%
Cash & Equivalents	$11.53M	$14.06M
Short-Term Investments
Other Short-Term Assets	$578.1K	$349.7K	$349.7K
YoY Change	-51.14%	-63.84%	-63.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$12.11M	$14.41M	$14.41M
YoY Change	-27.96%	394.87%	394.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$95.81K	$102.9K	$102.9K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$95.81K	$102.9K	$102.9K
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$12.11M	$14.41M	$14.41M
Total Long-Term Assets	$95.81K	$102.9K	$102.9K
Total Assets	$12.21M	$14.52M	$14.52M
YoY Change	-27.39%	398.4%	398.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.029M	$1.163M	$1.163M
YoY Change	-4.09%	130.91%	130.91%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.029M	$1.165M	$1.165M
YoY Change	-30.18%	29.49%	29.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.029M	$1.165M	$1.165M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.029M	$1.165M	$1.165M
YoY Change	-30.18%	29.49%	29.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.23M	-$29.19M
YoY Change	68.29%	73.44%
Common Stock	$9.548K	$9.548K
YoY Change		41.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.18M	$13.35M	$13.35M
YoY Change
Total Liabilities & Shareholders Equity	$12.21M	$14.52M	$14.52M
YoY Change	-27.39%	398.4%	398.4%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$3.037M	-$3.869M	-$12.36M
YoY Change	30.92%	207.87%	144.96%
Depreciation, Depletion And Amortization	$7.097K	$3.550K	$3.549K
YoY Change
Cash From Operating Activities	-$2.537M	-$1.562M	-$6.614M
YoY Change	107.47%	24.21%	143.88%
INVESTING ACTIVITIES
Capital Expenditures		-$106.5K	-$106.5K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities		-$106.5K	-$106.5K
YoY Change			-205.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.000M
YoY Change			185.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.942M	$18.85M
YoY Change		25.3%	323.7%
NET CHANGE
Cash From Operating Activities	-$2.537M	-1.562M	-$6.614M
Cash From Investing Activities		-106.5K	-$106.5K
Cash From Financing Activities		3.942M	$18.85M
Net Change In Cash	-$2.537M	2.274M	$12.13M
YoY Change		20.39%	559.85%
FREE CASH FLOW
Cash From Operating Activities	-$2.537M	-$1.562M	-$6.614M
Capital Expenditures		-$106.5K	-$106.5K
Free Cash Flow		-$1.456M	-$6.508M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	alxneuro	Noncash Expense From Issuance Of Common Stock NoncashExpenseFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty		usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022	alxneuro	Conversion Of Series A Convertible Stock ConversionOfSeriesAConvertibleStock		usd
CY2021	us-gaap	Depreciation Depreciation		usd
CY2022	alxneuro	Interest Expense Debt Discount Related Party InterestExpenseDebtDiscountRelatedParty		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001677077
CY2021	alxneuro	Conversion Of Series Preferred Stock ConversionOfSeriesPreferredStock		usd
CY2022	alxneuro	Fair Value Of Warrants Issued In Connection With Convertible Notes Payable Related Party FairValueOfWarrantsIssuedInConnectionWithConvertibleNotesPayableRelatedParty		usd
CY2022	alxneuro	Fair Value Of Warrants Issued In Connection With Convertible Notes Payable FairValueOfWarrantsIssuedInConnectionWithConvertibleNotesPayable		usd
CY2022	alxneuro	Issuance Of Common Stock In Payment Of Shortterm Advances Related Party IssuanceOfCommonStockInPaymentOfShorttermAdvancesRelatedParty		usd
CY2021Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q2	alxneuro	Fixed Assets FixedAssets		usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021	alxneuro	Purchase Of Machinery PurchaseOfMachinery		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	alxneuro	Proceeds From Shortterm Advances Related Party ProceedsFromShorttermAdvancesRelatedParty		usd
CY2021	alxneuro	Fair Value Of Warrants Issued In Connection With Ipo FairValueOfWarrantsIssuedInConnectionWithIpo		usd
CY2021	alxneuro	Fair Value Of Warrants Issued In Connection Securities Purchase Agreement Related Party FairValueOfWarrantsIssuedInConnectionSecuritiesPurchaseAgreementRelatedParty		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	alxneuro	Proceeds From Note Receivable For Common Stock Related Party ProceedsFromNoteReceivableForCommonStockRelatedParty		usd
CY2022	alxneuro	Proceeds From Convertible Note Payable ProceedsFromConvertibleNotePayable		usd
CY2022	alxneuro	Proceeds From Convertible Note Payable Related Party ProceedsFromConvertibleNotePayableRelatedParty		usd
CY2021	alxneuro	Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts		usd
CY2021	alxneuro	Issuance Of Common Stock On Conversion Of Note IssuanceOfCommonStockOnConversionOfNote		usd
CY2022	alxneuro	Issuance Of Common Stock In Payment Of Convertible Notes Payable Related Party IssuanceOfCommonStockInPaymentOfConvertibleNotesPayableRelatedParty		usd
CY2022	alxneuro	Accrued Interest Payable For Common Stock AccruedInterestPayableForCommonStock		usd
CY2021Q2	us-gaap	Prepaid Insurance PrepaidInsurance		usd
CY2022Q2	us-gaap	Other Receivables OtherReceivables		usd
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations		usd
CY2021	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations		usd
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M21D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11M1D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M13D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M24D
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y10M25D
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-04-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40483
CY2022	dei	Entity Registrant Name EntityRegistrantName	ALZAMEND NEURO, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1822909
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3500 Lenox Rd NE
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1500
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30326
CY2022	dei	City Area Code CityAreaCode	844
CY2022	dei	Local Phone Number LocalPhoneNumber	722-6333
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	ALZN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	109100000	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95481790	shares
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Name AuditorName	BAKER TILLY US, LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14063811	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1929270	usd
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	983320	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	349723	usd
CY2022	us-gaap	Interest Expense InterestExpense	46524	usd
CY2021	us-gaap	Interest Expense InterestExpense	142421	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	14413534	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	2912590	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	102909	usd
CY2022Q2	us-gaap	Assets Assets	14516443	usd
CY2021Q2	us-gaap	Assets Assets	2912590	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1162850	usd
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	503591	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2082	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	60749	usd
CY2021Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	335303	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1164932	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	899643	usd
CY2022Q2	us-gaap	Liabilities Liabilities	1164932	usd
CY2021Q2	us-gaap	Liabilities Liabilities	899643	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	75	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95481790	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95481790	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67429525	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67429525	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	9548	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	6743	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57419753	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33721860	usd
CY2022Q2	alxneuro	Note Receivable For Common Stock Related Party NoteReceivableForCommonStockRelatedParty	-14883295	usd
CY2021Q2	alxneuro	Note Receivable For Common Stock Related Party NoteReceivableForCommonStockRelatedParty	-14883295	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29194495	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16832436	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	13351511	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2012947	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14516443	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2912590	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5201314	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1310716	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7118221	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3641172	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	12319535	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	4951888	usd
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	821709	usd
CY2021	alxneuro	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	4000000	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	16382	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12319535	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-4951888	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	62418	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1706	usd
CY2021	alxneuro	Stockbased Compensation To Employees And Consultants StockbasedCompensationToEmployeesAndConsultants	2032359	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5046567	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-42524	usd
CY2022	us-gaap	Depreciation Depreciation	3549	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72650073	shares
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	12770	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-94679	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12362059	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5046567	usd
CY2022	alxneuro	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.14
CY2021	alxneuro	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.07
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89095274	shares
CY2021	alxneuro	Stock Issued During Period Value New Issues Two StockIssuedDuringPeriodValueNewIssuesTwo	99905	usd
CY2021	alxneuro	Fair Value Of Warrants Issued In Connection With Convertible Notes FairValueOfWarrantsIssuedInConnectionWithConvertibleNotes	91241	usd
CY2021	alxneuro	Fair Value Of Warrants Issued In Connection With Convertible Notes Related Party FairValueOfWarrantsIssuedInConnectionWithConvertibleNotesRelatedParty	14300	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5046567	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2012947	usd
CY2022	alxneuro	Stockbased Compensation To Employees And Consultants StockbasedCompensationToEmployeesAndConsultants	4408569	usd
CY2022	alxneuro	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	6000000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2200	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1500000	usd
CY2022	alxneuro	Stock Issued During Period Value New Issues Three StockIssuedDuringPeriodValueNewIssuesThree	12911456	usd
CY2022	alxneuro	Issuance Of Shares Of Common Stock For Conversion Of Debt IssuanceOfSharesOfCommonStockForConversionOfDebt	378398	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12362059	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	13351511	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12362059	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	124046	usd
CY2021	alxneuro	Interest Expense Debt Discount Related Party InterestExpenseDebtDiscountRelatedParty	14300	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	62418	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4408569	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2032359	usd
CY2021	alxneuro	Noncash Expense From Issuance Of Common Stock NoncashExpenseFromIssuanceOfCommonStock	378704	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-633597	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-260791	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	693584	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-413242	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6613990	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2712027	usd
CY2021	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	100915	usd
CY2022	alxneuro	Purchase Of Machinery PurchaseOfMachinery	-106458	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-106458	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	100915	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6000000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14063811	usd
CY2022	alxneuro	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross	-5500000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0004
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2100000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2200	usd
CY2022	alxneuro	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Cancelled Or Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited	300000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	300000	shares
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	58667	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.5000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	8800000	shares
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1918	usd
CY2021	alxneuro	Proceeds From Shortterm Advances Related Party ProceedsFromShorttermAdvancesRelatedParty	1850000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	62110	usd
CY2021	alxneuro	Cash And Cash Equivalents Period Increase Decrease1 CashAndCashEquivalentsPeriodIncreaseDecrease1	1838985	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1929270	usd
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90285	usd
CY2021	alxneuro	Proceeds From Note Receivable For Common Stock Related Party ProceedsFromNoteReceivableForCommonStockRelatedParty	99905	usd
CY2021	alxneuro	Proceeds From Convertible Note Payable ProceedsFromConvertibleNotePayable	290000	usd
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	353352	usd
CY2021Q2	us-gaap	Other Receivables OtherReceivables	16210	usd
CY2021	alxneuro	Proceeds From Convertible Note Payable Related Party ProceedsFromConvertibleNotePayableRelatedParty	50000	usd
CY2022	alxneuro	Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts	12911456	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18854989	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4450097	usd
CY2022	alxneuro	Cash And Cash Equivalents Period Increase Decrease1 CashAndCashEquivalentsPeriodIncreaseDecrease1	12134541	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1929270	usd
CY2022	alxneuro	Conversion Of Series Preferred Stock ConversionOfSeriesPreferredStock	1425	usd
CY2022	alxneuro	Fair Value Of Warrants Issued In Connection With Ipo FairValueOfWarrantsIssuedInConnectionWithIpo	194490	usd
CY2022	alxneuro	Fair Value Of Warrants Issued In Connection Securities Purchase Agreement Related Party FairValueOfWarrantsIssuedInConnectionSecuritiesPurchaseAgreementRelatedParty	5374509	usd
CY2021	alxneuro	Fair Value Of Warrants Issued In Connection With Convertible Notes Payable Related Party FairValueOfWarrantsIssuedInConnectionWithConvertibleNotesPayableRelatedParty	14300	usd
CY2021	alxneuro	Fair Value Of Warrants Issued In Connection With Convertible Notes Payable FairValueOfWarrantsIssuedInConnectionWithConvertibleNotesPayable	91241	usd
CY2021	alxneuro	Issuance Of Common Stock In Payment Of Shortterm Advances Related Party IssuanceOfCommonStockInPaymentOfShorttermAdvancesRelatedParty	1850000	usd
CY2022	alxneuro	Issuance Of Common Stock On Conversion Of Note IssuanceOfCommonStockOnConversionOfNote	378398	usd
CY2021	alxneuro	Issuance Of Common Stock In Payment Of Convertible Notes Payable Related Party IssuanceOfCommonStockInPaymentOfConvertibleNotesPayableRelatedParty	50000	usd
CY2021	alxneuro	Accrued Interest Payable For Common Stock AccruedInterestPayableForCommonStock	12498	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-12362059	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Cash Cash	14100000	usd
CY2022Q2	alxneuro	Retained Earnings Accumulated Deficit1 RetainedEarningsAccumulatedDeficit1	29200000	usd
CY2021Q2	us-gaap	Cash Cash	1900000	usd
CY2021Q2	alxneuro	Retained Earnings Accumulated Deficit1 RetainedEarningsAccumulatedDeficit1	16800000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	349723	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	575000	shares
CY2021Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	983320	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19425000	shares
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-5046567	usd
CY2021Q2	alxneuro	Prepaid Insurance1 PrepaidInsurance1	855000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12362059	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zECRDSvut7Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zKd0mqGWmEx6">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include research and development, share-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p>
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24037298	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38315634	shares
CY2022	alxneuro	Long Term Debt Average Amount Of Outstanding LongTermDebtAverageAmountOfOutstanding	14883295	usd
CY2021	alxneuro	Long Term Debt Average Amount Of Outstanding LongTermDebtAverageAmountOfOutstanding	14883295	usd
CY2022Q2	alxneuro	Prepaid Consulting Fees PrepaidConsultingFees	186667	usd
CY2021Q2	alxneuro	Prepaid Consulting Fees PrepaidConsultingFees	613758	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	155880	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7176	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.022	pure
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5046567	usd
CY2022	alxneuro	Stock Compensation Rate StockCompensationRate	0.130	pure
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8376539	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3360381	usd
CY2022Q2	alxneuro	Stock Compensation StockCompensation	1722003	usd
CY2021Q2	alxneuro	Stock Compensation StockCompensation	994264	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10098542	usd
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4354645	usd
CY2022Q2	alxneuro	Fixed Assets FixedAssets	-21611	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10076931	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4354645	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.123	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.186	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.463	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.345	pure
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.6964
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15609500	usd
CY2021	alxneuro	Stock Compensation Rate StockCompensationRate	-0.029	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000	pure
CY2021	alxneuro	Increase To Plan Shares IncreaseToPlanShares	10000000	shares
CY2021	alxneuro	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted	-125000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	125000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.5000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10450000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19550000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.7195
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	35159500	usd
CY2022	alxneuro	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted	-1950000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1950000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.7195
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10076931	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4354645	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15700000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.2017
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2219700	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13700000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.2311
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2179700	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	13460519	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.0345
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2155022	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022	alxneuro	Consulting Expenses ConsultingExpenses	383000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4408569	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2411063	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10149788	shares
CY2022Q2	alxneuro	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	2.90
CY2022Q2	alxneuro	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	10149788	shares
CY2022Q2	alxneuro	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	2.90
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001

Files In Submission

Name	View Source	Status
0001214659-22-008985-index-headers.html	Edgar Link	pending
0001214659-22-008985-index.html	Edgar Link	pending
0001214659-22-008985.txt	Edgar Link	pending
0001214659-22-008985-xbrl.zip	Edgar Link	pending
alxneuro-20220430.xsd	Edgar Link	pending
alxneuro-20220430_cal.xml	Edgar Link	unprocessable
alxneuro-20220430_def.xml	Edgar Link	unprocessable
alxneuro-20220430_lab.xml	Edgar Link	unprocessable
alxneuro-20220430_pre.xml	Edgar Link	unprocessable
ex23_1.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g7722110k.htm	Edgar Link	pending
g7722110k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
p13chart.jpg	Edgar Link	pending
p5chart.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALZN
Alzamend Neuro, Inc. Stock $alzn

2022 Q3 Form 10-K Financial Statement

#000121465922008985 Filed on July 19, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALZN Alzamend Neuro, Inc. Stock $alzn

2022 Q3 Form 10-K Financial Statement

#000121465922008985 Filed on July 19, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALZN
Alzamend Neuro, Inc. Stock $alzn